Systematic investigation and comparison of US FDA-approved immunosuppressive drugs FK506, cyclosporine and rapamycin for neuromuscular regeneration following chronic nerve compression injury

Regen Med. 2021 Nov;16(11):989-1003. doi: 10.2217/rme-2020-0130. Epub 2021 Oct 11.

Abstract

Aim: To compare therapeutic benefits of different immunophilin ligands for treating nerve injuries. Materials & methods: Cyclosporine, FK506 and rapamycin, were evaluated first in vitro on a serum-free culture of embryonic dorsal root ganglia followed by a new in vivo model of chronic nerve compression. Results: Outcomes of the in vitro study have shown a potent effect of cyclosporine and FK506, on dorsal root ganglia axonal outgrowth, comparable to the effect of nerve growth factor. Rapamycin exhibited only a moderate effect. The in vivo study revealed the beneficial effects of cyclosporine, FK506 and rapamycin for neuromuscular regeneration. Cyclosporine showed the better maintenance of the tissues and function. Conclusion: Cyclosporine, FK506 and rapamycin drugs showed potential for treating peripheral nerve chronic compression injuries.

Keywords: FK506; axonal regeneration; compression nerve injury; cyclosporine; muscle degeneration; myelin regeneration; rapamycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclosporine / pharmacology
  • Nerve Regeneration
  • Pharmaceutical Preparations*
  • Sirolimus / pharmacology
  • Tacrolimus* / pharmacology

Substances

  • Pharmaceutical Preparations
  • Cyclosporine
  • Sirolimus
  • Tacrolimus